Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert S. who wrote (9068)	3/10/1999 8:34:00 AM
From: opalapril	Read Replies (1) \| Respond to of 17367

Good series of posts! Got a couple questions. 1. (Robert S): <Interim monitoring has also been used to select one among many doses or different drugs> Anyone have facts indicating Xoma's trial also experiments with different dosage levels? 2. (Earlier post): <I think the Brits have something with their awareness campaign and the so called bottle test> How about Xoma spinning off an IPO -- "Meningo Patient Travel, Inc." (OTC: MPTI). Company has fleet of airplanes used to fly all USA patients to England, where the quality of care is so superior the chances of survival are more than twice as good.

To: Robert S. who wrote (9068)	3/10/1999 9:46:00 AM
From: aknahow	Read Replies (1) \| Respond to of 17367

Robert_S, thanks. best information on DSMB I have seen to date. At the risk of taking part of it out of context I was struck by this: "Based on these comprehensive analyses, the DSMB may recommend termination of the trial. In general, some of the considerations which enter into that decision are whether the accumulated data provide compelling, conclusive results with respect to the principal outcomes in an intention-to-treat analysis. Here this is not purely a matter of statistical significance for any one outcome. Rather, it is a matter of whether all of the objectives of the trial have been met, or alternately whether no further gains are expected to accrue if the trial were to continue to its originally designed conclusion." Given the supposedly FDA mandated target mortality, it would seem difficult for any DSMB to recommend termination before that, "objective of the trial", had been met. Other parts also seem to support this. I have a bias, and may be seeing only what I want to see.